Both revenues and adjusted earnings for the quarter topped the Zacks Consensus Estimate. Celanese currently holds a Zacks Rank #3 (Hold). Other Better-ranked stocks in the chemical space are Marrone Bio Innovations, Inc. ( MBII ), Ashland Inc. ( ASH ) and LyondellBasell Industries NV ( LYB ). While Marrone Bio Innovations sports a Zacks Rank #1 (Strong Buy), Ashland and LyondellBasell Industries carry a Zacks Rank #2 (Buy). Want the latest recommendations from Zacks Investment Research?
Transocean also mentioned that the estimated planned out-of-service time for 2014 has increased by net 141 days, while for the next year, this estimate has been extended by a net amount of 11 days. Transocean added that the net increase in 2014 out-of-service time includes 168 days related to the semi-submersible, Transocean Amirante. Switzerland-based Transocean is the world's largest offshore drilling contractor and the leading provider of drilling management services. The company's latest fleet comprises 77 mobile offshore drilling units that include 46 high-specification floaters, 21 midwater floaters and 10 high-specification jackups. Additionally, Transocean has nine ultra-deepwater drillships and five high-specification jackups in the construction phase. Though it has a strong backlog that provides support to earnings and cash flow, the company's exposure to the volatile and cyclical oil and gas exploration and production sector could limit deepwater drilling and lower equipment demand, thereby affecting bookings at Transocean. The company has consistently performed well in the past few quarters, reporting earnings well above the Zacks Consensus Estimate.
Pan American Silver Announces Strike at Bolivian Mine - Analyst Blog - NASDAQ.com
Access is currently allowed to only those who are responsible for maintenance of critical systems necessary to enable a smooth restart. The work, which was stopped on Jul 7, 2014, has had no material impact on Pan American to date. However, if the shut-down is extended then there will be an adverse impact on the annual production forecast for the San Vicente mine and eventually Pan American.
The Zacks Analyst Blog Highlights: AbbVie, Shire, Gilead Sciences, Sarepta Therapeutics and Celgene - Yahoo Finance
This time around, it looks like a deal can materialize with Shire indicating its willingness to recommend the offer to its shareholders provided certain other terms are resolved. If the acquisition goes through, AbbVie will join a string of U.S. 2. Sarepta, which focuses on the discovery and development of RNA-based therapeutics for rare and infectious diseases, saw its shares tumbling on 144-week data on its experimental Duchenne muscular dystrophy treatment, eteplirsen. Investors were disappointed with the 144-week data on decline in walking distance which was considered to be weaker than the 120-week data presented earlier this year. Despite this, Sarepta remains committed to file for regulatory approval in the U.S. 3.
Cousins Properties on Growth Track with Restructuring Efforts - Analyst Blog - NASDAQ.com
Moreover, the company focuses on increasing the value of its current portfolio by inking long-term lease deals with high-end tenants. Notably, the pre-leasing deal with Earth Fare for Emory Point Phase II, inked in May, reflects the strong demand for the company's assets. Also, Cousins Properties aims towards maintaining a flexible balance sheet with ample liquidity to not only capitalize on opportunistic acquisitions but also leverage on improving market fundamentals and raise operational efficiency. In May, fueled by a significant rise in revenues, Cousins Properties reported an earnings surprise of 11.8% for first-quarter 2014. In particular, the company reported FFO of 19 cents per share, surpassing the Zacks Consensus Estimate by 2 cents as well as the year-ago figure by 8 cents. However, stiff competition and sluggish office space demand due to adequate space availability exerts pressure on rent and occupancies.